Giant extragastrointestinal stromal tumor in the transverse mesocolon concomitant with gastric cancer in an elderly patient: Case report

Department of General Surgery, Qilu Hospital, Shandong University, Jinan 250012, P.R. China.
Oncology letters (Impact Factor: 1.55). 02/2013; 5(2):627-630. DOI: 10.3892/ol.2012.1030
Source: PubMed


Extragastrointestinal stromal tumors (EGISTs) are neoplasms located outside the gastrointestinal tract in sites including the omentum, mesentery and retroperitoneum. EGISTs of the transverse mesocolon are rarely noted in the literature. Herein, we describe a rare case of giant EGIST concomitant with gastric cancer in a 78-year-old male who presented with upper abdominal pain and a palpable mass. The patient underwent en bloc resection of the tumor with a distal gastrectomy, with a D2 lymphadenectomy for the gastric cancer, accompanied with resection of a segment of the transverse colon. The patient received targeted therapy (imatinib 400 mg, daily) and adjuvant chemotherapy with FOLFOX (six cycles). Neither recurrence nor metastasis was observed after 24 months of follow-up.

  • Source
    • "Surgical resection is currently the primary treatment option for non-metastatic EGISTs (6). For prostatic masses, transrectal ultrasound-guided prostate biopsies may assist in the determination of a treatment strategy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Extragastrointestinal stromal tumors (EGISTs), which are neoplasms outside the digestive tract, are predominantly observed in the greater omentum and retroperitoneum. The clinicopathological and molecular characteristics of EGISTs are similar to those of gastrointestinal stromal tumors (GISTs). EGISTs originating from the prostate are extremely rare. In this study, we report a case of a prostatic EGIST in a 39-year-old male, who presented with frequency, urgency, dysuria and a prostatic mass. A 10-core transrectal ultrasound-guided prostate biopsy was performed, and the histological and immunohistochemical results confirmed the diagnosis of EGIST. The patient received a radical prostatectomy, followed by targeted therapy with imatinib (400 mg, daily) for 1 year. Neither recurrence nor metastasis was detected at a 24-month follow-up.
    Full-text · Article · Aug 2013 · Experimental and therapeutic medicine